Genentech to Advance Curis' Cancer Treatment to Phase II

Genentech has notified Curis of its decision to progress a systemically administered hedgehog antagonist drug candidate to Phase II testing in the first half of 2008.

The candidate will be evaluated in one or more solid tumor indications.

Once the trial begins, Curis is eligible to receive cash milestone payments from Genentech under the parties’ June 2003 agreement, Curis said.